Blackhill Capital Inc. Sells 5,140 Shares of Johnson & Johnson $JNJ

Key Points

• Blackhill Capital Inc. has reduced its stake in Johnson & Johnson by 7.0%, selling 5,140 shares, and now holds 68,187 shares, worth approximately $11.3 million.
• Analysts have varied ratings for JNJ, with Barclays and Royal Bank of Canada raising price targets significantly, while Wall Street Zen downgraded its rating from "strong-buy" to "buy".
• Johnson & Johnson reported a quarterly earnings per share (EPS) of $2.77, beating expectations, and announced a quarterly dividend of $1.30 per share, reflecting a dividend yield of 2.9%.

Blackhill Capital Inc. lowered its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 7.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 68,187 shares of the company's stock after selling 5,140 shares during the quarter. Johnson & Johnson makes up about 0.7% of Blackhill Capital Inc.'s investment portfolio, making the stock its 13th largest holding. Blackhill Capital Inc.'s holdings in Johnson & Johnson were worth $11,308,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Highline Wealth Partners LLC increased its position in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after buying an additional 86 shares during the last quarter. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $47,000. von Borstel & Associates Inc. acquired a new stake in Johnson & Johnson during the 1st quarter valued at $49,000. Harvest Fund Management Co. Ltd bought a new position in Johnson & Johnson during the first quarter worth $52,000. Finally, Capital A Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at $50,000. 69.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

JNJ has been the subject of several research reports. Barclays raised their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Royal Bank Of Canada lifted their target price on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Wall Street Zen cut shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Finally, Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $178.5890 on Thursday. The firm has a 50 day moving average of $162.59 and a 200-day moving average of $158.87. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $180.61. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $430.10 billion, a PE ratio of 19.10, a PEG ratio of 2.26 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same period last year, the firm posted $2.82 earnings per share. The firm's quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. Johnson & Johnson's dividend payout ratio is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.